Exhibit 12.1
Vertex Pharmaceuticals Incorporated
Computation of Ratio of Earnings to Fixed Charges
(Amounts in thousands)
|
|
|
|
|
|
|
|
|
|
|
| Six Months Ended |
| ||||||
|
| Year ended December 31, |
| June 30, |
| ||||||||||||||
|
| 2009 |
| 2008 |
| 2007 |
| 2006 |
| 2005 |
| 2010 |
| ||||||
Loss from continuing operations before cumulative effect of a change in accounting principle |
| $ | (642,178 | ) | $ | (459,851 | ) | $ | (391,279 | ) | $ | (207,937 | ) | $ | (203,417 | ) | $ | (365,277 | ) |
Fixed charges: |
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Interest expense and amortization of deferred issuance costs |
| 13,192 |
| 13,471 |
| 2,285 |
| 7,955 |
| 17,326 |
| 7,638 |
| ||||||
Appropriate rental obligations |
| 17,827 |
| 14,901 |
| 13,520 |
| 15,938 |
| 14,736 |
| 9,765 |
| ||||||
Total fixed charges |
| $ | 31,019 |
| $ | 28,372 |
| $ | 15,805 |
| $ | 23,893 |
| $ | 32,062 |
| $ | 17,403 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Loss from continuing operations before cumulative effect of a change in accounting principle, plus fixed charges |
| $ | (611,159 | ) | $ | (431,479 | ) | $ | (375,474 | ) | $ | (184,044 | ) | $ | (171,355 | ) | $ | (347,874 | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Ratio of earnings to fixed charges |
| * |
| * |
| * |
| * |
| * |
| * |
|
* | Due to the Company’s loss from continuing operations before cumulative effect of a change in accounting principle, earnings were insufficent to cover fixed charges by $365,277,000 for the six months ended June 30, 2010 and earnings were insufficent to cover fixed charges by $642,178,000, $459,851,000, $391,279,000, $207,937,000 and $203,417,000, respectively, for the years ended December 31, 2009, 2008, 2007, 2006 and 2005. |